{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:41:57Z","timestamp":1793659317501,"version":"4.5.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Porto IBD group of ESPGHAN"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40262-025-01565-6","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:43:57Z","timestamp":1761749037000},"page":"81-95","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Population Pharmacokinetics Analysis of Infliximab in up to 10-Year-Old Patients with Paediatric Inflammatory Bowel Disease: Label-Recommended Dose Fails to Achieve Therapeutic Target Concentration"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5800-0966","authenticated-orcid":false,"given":"Q.","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M. E","family":"Jongsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Vuijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. C. M.","family":"de Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Martinez-Vinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. L.","family":"Kolho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Norsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hussey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan","family":"Wine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomi","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dror S.","family":"Shouval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Assa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Lev-Tzion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"de Meij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victorien M.","family":"Wolters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien Q.","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Preijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"de Ridder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"1565_CR1","unstructured":"Remicade. EPAR\u2014Product information. 2009. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remicade-epar-product-information_en.pdf."},{"issue":"1","key":"1565_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/mpg.0000000000002112","volume":"68","author":"S Naviglio","year":"2019","unstructured":"Naviglio S, Lacorte D, Lucaf\u00f2 M, et al. Causes of treatment failure in children with inflammatory bowel disease treated with infliximab: a pharmacokinetic study. J Pediatr Gastroenterol Nutr. 2019;68(1):37\u201344. https:\/\/doi.org\/10.1097\/mpg.0000000000002112.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"1565_CR3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","volume":"132","author":"J Hyams","year":"2007","unstructured":"Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children. Gastroenterology. 2007;132(3):863\u201373. https:\/\/doi.org\/10.1053\/j.gastro.2006.12.003.","journal-title":"Gastroenterology"},{"issue":"5","key":"1565_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/s2468-1253(19)30012-3","volume":"4","author":"NA Kennedy","year":"2019","unstructured":"Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341\u201353. https:\/\/doi.org\/10.1016\/s2468-1253(19)30012-3.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"1565_CR5","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1097\/mib.0000000000000137","volume":"20","author":"N Singh","year":"2014","unstructured":"Singh N, Rosenthal CJ, Melmed GY, et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(10):1708\u201313. https:\/\/doi.org\/10.1097\/mib.0000000000000137.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"1565_CR6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/mpg.0000000000002051","volume":"67","author":"B Ungar","year":"2018","unstructured":"Ungar B, Glidai Y, Yavzori M, et al. Association between infliximab drug and antibody levels and therapy outcome in pediatric inflammatory bowel diseases. J Pediatr Gastroenterol Nutr. 2018;67(4):507\u201312. https:\/\/doi.org\/10.1097\/mpg.0000000000002051.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1565_CR7","doi-asserted-by":"publisher","unstructured":"Xu Z, Davis HM, Zhou H. Rational development and utilization of antibody-based therapeutic proteins in pediatrics. Pharmacol Ther. 2013;137(2):225\u201347.  https:\/\/doi.org\/10.1016\/j.pharmthera.2012.10.005. Epub 2012 Oct 23. PMID: 23092685.","DOI":"10.1016\/j.pharmthera.2012.10.005"},{"issue":"12","key":"1565_CR8","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1093\/rheumatology\/kem261","volume":"46","author":"M Svenson","year":"2007","unstructured":"Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford). 2007;46(12):1828\u201334. https:\/\/doi.org\/10.1093\/rheumatology\/kem261.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"1565_CR9","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/apt.12030","volume":"36","author":"N Vande Casteele","year":"2012","unstructured":"Vande Casteele N, Buurman DJ, Sturkenboom MG, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther. 2012;36(8):765\u201371. https:\/\/doi.org\/10.1111\/apt.12030.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"1565_CR10","doi-asserted-by":"publisher","first-page":"e287","DOI":"10.1515\/cclm-2013-0461","volume":"51","author":"B Ruiz-Arg\u00fcello","year":"2013","unstructured":"Ruiz-Arg\u00fcello B, del Agua AR, Torres N, Monasterio A, Mart\u00ednez A, Nagore D. Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med. 2013;51(12):e287\u20139. https:\/\/doi.org\/10.1515\/cclm-2013-0461.","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"1565_CR11","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1097\/mpg.0000000000000533","volume":"59","author":"JR Kelsen","year":"2014","unstructured":"Kelsen JR, Grossman AB, Pauly-Hubbard H, Gupta K, Baldassano RN, Mamula P. Infliximab therapy in pediatric patients 7 years of age and younger. J Pediatr Gastroenterol Nutr. 2014;59(6):758\u201362. https:\/\/doi.org\/10.1097\/mpg.0000000000000533.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"12","key":"1565_CR12","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1007\/s00431-020-03750-0","volume":"179","author":"MME Jongsma","year":"2020","unstructured":"Jongsma MME, Winter DA, Huynh HQ, et al. Infliximab in young paediatric IBD patients: it is all about the dosing. Eur J Pediatr. 2020;179(12):1935\u201344. https:\/\/doi.org\/10.1007\/s00431-020-03750-0.","journal-title":"Eur J Pediatr"},{"issue":"6","key":"1565_CR13","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/cpt.2148","volume":"109","author":"Y Xiong","year":"2021","unstructured":"Xiong Y, Mizuno T, Colman R, et al. Real-world infliximab pharmacokinetic study informs an electronic health record-embedded dashboard to guide precision dosing in children with Crohn\u2019s disease. Clin Pharmacol Ther. 2021;109(6):1639\u201347. https:\/\/doi.org\/10.1002\/cpt.2148.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1565_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1373\/jalm.2018.027136","volume":"3","author":"MH Perry","year":"2018","unstructured":"Perry MH, McDonald TJ. Method comparison between ELISAs suggests therapeutic ranges for infliximab should be assay-specific. J Appl Lab Med. 2018;3(3):515\u20137. https:\/\/doi.org\/10.1373\/jalm.2018.027136.","journal-title":"J Appl Lab Med"},{"key":"1565_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2019.154859","volume":"126","author":"D Bertin","year":"2020","unstructured":"Bertin D, Serrero M, Grimaud JC, Desjeux A, Desplat-J\u00e9go S. Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: a comparison of three commercially available ELISA kits. Cytokine. 2020;126:154859. https:\/\/doi.org\/10.1016\/j.cyto.2019.154859.","journal-title":"Cytokine"},{"key":"1565_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13091368","author":"C Schr\u00e4pel","year":"2021","unstructured":"Schr\u00e4pel C, Kovar L, Selzer D, et al. External model performance evaluation of twelve infliximab population pharmacokinetic models in patients with inflammatory bowel disease. Pharmaceutics. 2021. https:\/\/doi.org\/10.3390\/pharmaceutics13091368.","journal-title":"Pharmaceutics"},{"issue":"4","key":"1565_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40262-024-01354-7","volume":"63","author":"NC Bevers","year":"2024","unstructured":"Bevers NC, Keizer RJ, Wong DR, et al. Performance of eight infliximab population pharmacokinetic models in a cohort of Dutch children with inflammatory bowel disease. Clin Pharmacokinet. 2024;63(4):529\u201338. https:\/\/doi.org\/10.1007\/s40262-024-01354-7.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1565_CR18","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/a:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481\u2013504. https:\/\/doi.org\/10.1023\/a:1012299115260.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"1565_CR19","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/j.1552-4604.1997.tb04326.x","volume":"37","author":"EI Ette","year":"1997","unstructured":"Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37(6):486\u201395. https:\/\/doi.org\/10.1002\/j.1552-4604.1997.tb04326.x.","journal-title":"J Clin Pharmacol"},{"key":"1565_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa161","author":"PF van Rheenen","year":"2020","unstructured":"van Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric Crohn\u2019s disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis. 2020. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa161. (Oct 7).","journal-title":"J Crohns Colitis"},{"issue":"5","key":"1565_CR21","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s10620-022-07783-3","volume":"68","author":"A Chung","year":"2023","unstructured":"Chung A, Carroll M, Almeida P, et al. Early infliximab clearance predicts remission in children with Crohn\u2019s disease. Dig Dis Sci. 2023;68(5):1995\u20132005. https:\/\/doi.org\/10.1007\/s10620-022-07783-3.","journal-title":"Dig Dis Sci"},{"issue":"7","key":"1565_CR22","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","volume":"33","author":"AA Fasanmade","year":"2011","unstructured":"Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM. Pharmacokinetic properties of infliximab in children and adults with Crohn\u2019s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33(7):946\u201364. https:\/\/doi.org\/10.1016\/j.clinthera.2011.06.002.","journal-title":"Clin Ther"},{"issue":"3","key":"1565_CR23","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/ibd\/izz143","volume":"26","author":"LE Bauman","year":"2020","unstructured":"Bauman LE, Xiong Y, Mizuno T, et al. Improved population pharmacokinetic model for predicting optimized infliximab exposure in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2020;26(3):429\u201339. https:\/\/doi.org\/10.1093\/ibd\/izz143.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"1565_CR24","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1093\/ibd\/izad307","volume":"30","author":"RJ Colman","year":"2024","unstructured":"Colman RJ, Vuijk SA, Math\u00f4t RAA, et al. Infliximab monotherapy vs combination therapy for pediatric Crohn\u2019s disease exhibit similar pharmacokinetics. Inflamm Bowel Dis. 2024;30(10):1678\u201385. https:\/\/doi.org\/10.1093\/ibd\/izad307.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"1565_CR25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40272-024-00621-1","volume":"26","author":"S Clemente-Bautista","year":"2024","unstructured":"Clemente-Bautista S, Troc\u00f3niz IF, Segarra-Cant\u00f3n \u00d3, et al. The effect of polymorphisms and other biomarkers on infliximab exposure in paediatric inflammatory bowel disease: development of a population pharmacokinetic model. Paediatr Drugs. 2024;26(3):331\u201346. https:\/\/doi.org\/10.1007\/s40272-024-00621-1.","journal-title":"Paediatr Drugs"},{"issue":"2","key":"1565_CR26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3109\/10799893.2013.865745","volume":"34","author":"Z Tian","year":"2014","unstructured":"Tian Z, Sutton BJ, Zhang X. Distribution of rat neonatal Fc receptor in the principal organs of neonatal and pubertal rats. J Recept Signal Transduct Res. 2014;34(2):137\u201342. https:\/\/doi.org\/10.3109\/10799893.2013.865745.","journal-title":"J Recept Signal Transduct Res"},{"key":"1565_CR27","doi-asserted-by":"publisher","unstructured":"Brandse JF, Mould D, Smeekes O, Ashruf Y, Kuin S, Strik A, vanden Brink GR, D\u2019Haens GR. A real-life population pharmacokinetic study reveals factors associated with\nclearance and immunogenicity of infliximab in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(4):650\u201360. https:\/\/doi.org\/10.1097\/MIB.0000000000001043. PMID: 28195852.","DOI":"10.1097\/MIB.0000000000001043"},{"issue":"Dec","key":"1565_CR28","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1080\/17512433.2021.2028619","volume":"14","author":"W Kantasiripitak","year":"2021","unstructured":"Kantasiripitak W, Wang Z, Spriet I, Ferrante M, Dreesen E. Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases. Expert Rev Clin Pharmacol. 2021;14(Dec):1455\u201366. https:\/\/doi.org\/10.1080\/17512433.2021.2028619.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"Suppl 3","key":"1565_CR29","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1002\/jcph.382","volume":"55","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Wei X, Bajaj G, et al. Challenges and considerations for development of therapeutic proteins in pediatric patients. J Clin Pharmacol. 2015;55(Suppl 3):S103\u201315. https:\/\/doi.org\/10.1002\/jcph.382.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1565_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","volume":"9","author":"L Liu","year":"2018","unstructured":"Liu L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell. 2018;9(1):15\u201332. https:\/\/doi.org\/10.1007\/s13238-017-0408-4.","journal-title":"Protein Cell"},{"key":"1565_CR31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1542\/peds.28.2.169","volume":"28","author":"B Friis-Hansen","year":"1961","unstructured":"Friis-Hansen B. Body water compartments in children: changes during growth and related changes in body composition. Pediatrics. 1961;28:169\u201381.","journal-title":"Pediatrics"},{"issue":"12","key":"1565_CR32","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157\u201367. https:\/\/doi.org\/10.1056\/NEJMra035092.","journal-title":"N Engl J Med"},{"issue":"2","key":"1565_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/00365521.2020.1856405","volume":"56","author":"AS Strik","year":"2021","unstructured":"Strik AS, L\u00f6wenberg M, Mould DR, et al. Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. Scand J Gastroenterol. 2021;56(2):145\u201354. https:\/\/doi.org\/10.1080\/00365521.2020.1856405.","journal-title":"Scand J Gastroenterol"},{"issue":"Supplement_1","key":"1565_CR34","doi-asserted-by":"publisher","first-page":"S063","DOI":"10.1093\/ecco-jcc\/jjy222.090","volume":"13","author":"A Strik","year":"2019","unstructured":"Strik A, Berends S, Mould D, et al. DOP56 dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial. J Crohns Colitis. 2019;13(Supplement_1):S063\u2013S063.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"1565_CR35","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1208\/s12248-017-0082-8","volume":"19","author":"J Wojciechowski","year":"2017","unstructured":"Wojciechowski J, Upton RN, Mould DR, Wiese MD, Foster DJR. Infliximab maintenance dosing in inflammatory bowel disease: an example for in silico assessment of adaptive dosing strategies. AAPS J. 2017;19(4):1136\u201347. https:\/\/doi.org\/10.1208\/s12248-017-0082-8.","journal-title":"AAPS J"},{"issue":"3","key":"1565_CR36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/sji.12572","volume":"86","author":"LI Bader","year":"2017","unstructured":"Bader LI, Solberg SM, Kaada SH, et al. Assays for infliximab drug levels and antibodies: a matter of scales and categories. Scand J Immunol. 2017;86(3):165\u201370. https:\/\/doi.org\/10.1111\/sji.12572.","journal-title":"Scand J Immunol"},{"key":"1565_CR37","doi-asserted-by":"publisher","first-page":"175628482096579","DOI":"10.1177\/1756284820965790","volume":"13","author":"C Rocha","year":"2020","unstructured":"Rocha C, Lago P, Fernandes S, et al. Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays. Ther Adv Gastroenterol. 2020;13:1756284820965790. https:\/\/doi.org\/10.1177\/1756284820965790.","journal-title":"Ther Adv Gastroenterol"},{"issue":"7","key":"1565_CR38","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s40262-020-00874-2","volume":"59","author":"A Bensalem","year":"2020","unstructured":"Bensalem A, Ternant D. Pharmacokinetic variability of therapeutic antibodies in humans: a comprehensive review of population pharmacokinetic modeling publications. Clin Pharmacokinet. 2020;59(7):857\u201374. https:\/\/doi.org\/10.1007\/s40262-020-00874-2.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"1565_CR39","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s40262-017-0535-3","volume":"56","author":"N Vande Casteele","year":"2017","unstructured":"Vande Casteele N, Mould DR, Coarse J, et al. Accounting for pharmacokinetic variability of certolizumab pegol in patients with Crohn\u2019s disease. Clin Pharmacokinet. 2017;56(12):1513\u201323. https:\/\/doi.org\/10.1007\/s40262-017-0535-3.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"1565_CR40","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00228-009-0718-4","volume":"65","author":"AA Fasanmade","year":"2009","unstructured":"Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009;65(12):1211\u201328. https:\/\/doi.org\/10.1007\/s00228-009-0718-4.","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"1565_CR41","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1093\/ibd\/izy129","volume":"24","author":"A Petitcollin","year":"2018","unstructured":"Petitcollin A, Leuret O, Tron C, et al. Modeling immunization to infliximab in children with Crohn\u2019s disease using population pharmacokinetics: a pilot study. Inflamm Bowel Dis. 2018;24(8):1745\u201354. https:\/\/doi.org\/10.1093\/ibd\/izy129.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"1565_CR42","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/apt.13299","volume":"42","author":"DJ Buurman","year":"2015","unstructured":"Buurman DJ, Maurer JM, Keizer RJ, Kosterink JG, Dijkstra G. Population pharmacokinetics of infliximab in patients\nwith inflammatory bowel disease: potential implications for dosing in clinical practice. Aliment Pharmacol Ther. 2015;42(5):529\u201339. https:\/\/doi.org\/10.1111\/apt.13299.","journal-title":"Aliment Pharmacol Ther"},{"key":"1565_CR43","doi-asserted-by":"publisher","unstructured":"Magro F, Fernandes S, Patita M, Arroja B, Lago P, Rosa I, et al. The influence of subclinical active inflammation on IFX pharmacokinetic modeling and disease progression assessment: Findings from a prospective real-world study in inflammatory bowel disease patients. J Crohns Colitis. 2024;18(7):1102\u201312. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae014.","DOI":"10.1093\/ecco-jcc\/jjae014"},{"key":"1565_CR44","doi-asserted-by":"publisher","unstructured":"Edlund H, Steenholdt C, Ainsworth MA, Goebgen E, Brynskov J, Thomsen O\u00d8, et al. Magnitude of increased infliximab clearance imposed by anti-infliximab antibodies in Crohn\u2019s disease is determined by their concentration. AAPS J [Internet]. 2017;19(1):223\u201333. https:\/\/doi.org\/10.1208\/s12248-016-9989-8.","DOI":"10.1208\/s12248-016-9989-8"}],"updated-by":[{"DOI":"10.1007\/s40262-025-01599-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000}}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01565-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01565-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01565-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T18:01:56Z","timestamp":1768154516000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01565-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1565"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01565-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The author\u2019s name Victorien M. Wolters was incorrectly written without the mid-initial as Victorien Wolters.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40262-025-01599-w","URL":"https:\/\/doi.org\/10.1007\/s40262-025-01599-w","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding was received from Porto IBD group of ESPGHAN.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The datasets generated during and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Ethics committee approval was either waived or obtained in all participating centres.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The study was not subject to the Dutch Medical Research Involving Human Subjects Act (WMO), and therefore written informed consent was not required for all subjects.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The code used during the current study is available from the corresponding author on reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Q. Zhao conducted model analysis and manuscript preparation. M.M.E Jongsma and S.A. Vuijk collected the data. T. Preijers and B.C.M. de Winter supervised Q. Zhao on the population PK analysis and model construction. L. de Ridder designed this study. C. Martinez-Vinson, K.L. Kolho, Lorenzo Norsa, S. Hussey, Eytan Wine, Shlomi Cohen, Dror S. Shouval, Amit Assa, R. Lev-Tzion, Tim de Meij, Victorien  M. Wolters and Hien Q. Huynh participated in the clinical trial conduction. All authors reviewed and approved the manuscript before submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions:"}}]}}